These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32660375)

  • 1. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
    Guyader GL; Vieillard V; Paul M
    J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline) for extended duration.
    Vats B; Goyal P; Mathew Z; Ghosh R; Babu MN; Jadav RS; Nair AM; Subbarao M; Bera A; Prakash Sadasivappa K; Kabadi P; Sarkar A; Honnappa CG; Patnaik US; Singh A; Parambath AV; Ullanat R
    Expert Opin Biol Ther; 2022 Feb; 22(2):299-311. PubMed ID: 33896318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera
    Weiser S; Burns C; Zartler ER
    J Oncol Pharm Pract; 2023 Apr; 29(3):590-600. PubMed ID: 35072574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-month stability study of a biosimilar of infliximab (Remsima
    Vieillard V; Astier A; Sauzay C; Paul M
    Ann Pharm Fr; 2017 Jan; 75(1):17-29. PubMed ID: 27659414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of biosimilar trastuzumab MYL-1401O in HER2-positive breast cancer.
    Eser K; Sezer E; Erçolak V; İnal A
    Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab.
    Yang C; Khwaja R; Tang P; Nixon N; King K; Lupichuk S
    Curr Oncol; 2022 Jun; 29(6):4224-4234. PubMed ID: 35735446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N; Chennell P; Le Basle Y; Sautou V
    J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
    Kim SJ; Lee JW; Kang HY; Kim SY; Shin YK; Kim KW; Oh JS; Lim KJ; Kim JY
    BioDrugs; 2018 Dec; 32(6):619-625. PubMed ID: 30386977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.
    Audran R; Chtioui H; Thierry AC; Mayor CE; Vallotton L; Dao K; Rothuizen LE; Maghraoui A; Pennella EJ; Brunner-Ferber F; Buclin T; Spertini F
    Sci Rep; 2024 Jun; 14(1):12872. PubMed ID: 38834577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.
    Yun J; Kim J; Chung J; Hwang SJ; Park SJ
    Adv Ther; 2019 Jul; 36(7):1700-1714. PubMed ID: 31102205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.
    Bardo-Brouard P; Vieillard V; Shekarian T; Marabelle A; Astier A; Paul M
    Eur J Cancer; 2016 May; 58():8-16. PubMed ID: 26922168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D; Kim J; Yun J; Park SJ
    Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.
    Vieillard V; Le Guyader G; Jallades A; Astier A
    J Oncol Pharm Pract; 2024 Jan; 30(1):142-150. PubMed ID: 37078110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
    Hui A; Yin J; Liu W; Zheng K
    Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags.
    Vieillard V; Paul M; Ibrahim T; Astier A
    Ann Pharm Fr; 2017 Nov; 75(6):420-435. PubMed ID: 28784243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
    Vimpolsek M; Gottar-Guillier M; Rossy E
    Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
    Lamanna WC; Heller K; Schneider D; Guerrasio R; Hampl V; Fritsch C; Schiestl M
    J Oncol Pharm Pract; 2019 Mar; 25(2):269-278. PubMed ID: 28950806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
    Weiser S; Burns C; Zartler ER
    J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.